scholarly journals Programmed cell death protein blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation in an adolescent patient

2021 ◽  
Author(s):  
Irtiza Sheikh ◽  
Cesar Nunez ◽  
David McCall ◽  
Michael Roth ◽  
Branko Cuglievan
Keyword(s):  
Cell Death ◽  
Stem Cell ◽  
Programmed Cell Death ◽  
Stem Cell Transplantation ◽  
Hodgkin Lymphoma ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Adolescent Patient ◽  
Classical Hodgkin Lymphoma ◽  
Cell Death Protein

Reassessment of risk factors and long‐term results of autologous stem cell transplantation in relapsed and refractory classical Hodgkin lymphoma

2019 ◽  
Vol 37 (3) ◽  
pp. 310-313
Author(s):  
Giancarlo Fatobene ◽  
Camila da Cruz Gouveia Linardi ◽  
Frederico Moreira ◽  
Gabriela Matos Falcão Targueta ◽  
Fernanda Maria Santos ◽  
...  
Keyword(s):  
Risk Factors ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Hodgkin Lymphoma ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Long Term Results ◽  
Classical Hodgkin Lymphoma

scholarly journals Low Soluble Programmed Cell Death Protein 1 Levels After Allogeneic Stem Cell Transplantation Predict Moderate or Severe Chronic GvHD and Inferior Overall Survival

2021 ◽  
Vol 12 ◽  
Author(s):  
Lambros Kordelas ◽  
Ulrike Buttkereit ◽  
Falko M. Heinemann ◽  
Peter A. Horn ◽  
Bernd Giebel ◽  
...  
Keyword(s):  
Overall Survival ◽  
Cell Death ◽  
Stem Cell ◽  
Programmed Cell Death ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Plasma Levels ◽  
Chronic Gvhd ◽  
Hematopoietic Stem ◽  
Cell Death Protein

Programmed cell death protein-1 (PD-1) is an inhibitory co-receptor required for regulating immune responsiveness and maintaining immune homeostasis. As PD-1 can be released as bioactive soluble molecule, we investigated the clinical significance of soluble PD-1 (sPD-1) after allogeneic hematopoietic stem cell transplantation (HSCT) regarding graft-versus-host disease (GvHD), relapse, and overall survival (OS) in a mono-centric cohort of 82 patients. Compared to pre-HSCT and to healthy controls, post-HSCT sPD-1 plasma levels were significantly increased during an observation time of three months. Univariate analysis revealed that low sPD-1 plasma levels at month one, two or three post HSCT were associated with acute GvHD grade III-IV, the onset of moderate/severe chronic GvHD (cGvHD) and inferior OS, DFS, and TRM, respectively. No relationship was detected to relapse rates. sPD-1 plasma levels were significantly increased in ATG-treated patients compared to ATG-untreated patients. Multivariate analysis revealed that a low sPD-1 plasma levels status at one or two month(s) after HSCT is an independent indicator for inferior OS, DFS, or TRM. A low sPD-1 plasma levels status at month three post HSCT is predictive for the onset of moderate/severe cGvHD. Thus, our study pinpoints the soluble inhibitory co-receptor PD-1 as a promising candidate molecule for the prediction of clinical HSCT outcome.

Sign in / Sign up

Export Citation Format

Share Document